Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Hospital, 95122, Catania, Italy.
J Endocrinol Invest. 2024 Jul;47(7):1691-1700. doi: 10.1007/s40618-023-02270-6. Epub 2024 Mar 25.
Patients with beta-thalassemia major (BTM) often develop several endocrine disorders due to chronic iron overload. They are also prone to osteoporosis and vertebral fractures. Plasmatic insulin-like growth factor-1 (IGF-1) levels are often low in subjects with BTM, which origin is multifactorial. The aim of this study was to evaluate a possible relationship between serum IGF-1 levels and the presence of osteoporosis and/or vertebral fractures.
We retrospectively evaluated the occurrence of vertebral fractures in 30 adult male patients affected by BTM (mean age 43.3 ± 7.9 years) with low serum IGF-1 (median value 52.4 ng/ml, 38.5-83.4). Only 6 of them (20.0%) were diagnosed with GH deficiency (GHD) after GHRH/arginine stimulation test, while 23 (76.7%) had osteoporosis and 12 (40.0%) had known vertebral fractures. All patients except one also showed at least one endocrine disorder.
Serum IGF-1 was significantly lower in BTM patients with vertebral fractures compared to patients without vertebral fractures (U = 41.0, p = 0.005) while it was not significantly different between patients with low bone mass compared to patients without low bone mass. The diagnosis of GHD was significantly associated with lower serum IGF-1 (p = 0.001) and vertebral fractures (p = 0.002) but not with low bone mass. After ROC analysis, we found that very low IGF-1 (≤ 50.0 ng/dl) was associated with vertebral fractures (sensitivity 83.3%, specificity 75.0%) and was also predictive of GHD (sensitivity 75.0%, specificity 100.0%).
Our study shows that, in male patients with BTM, serum IGF-1 ≤ 50.0 ng/dl is a marker of vertebral fractures and it is predictive of a diagnosis of GHD.
由于慢性铁过载,重型β地中海贫血(BTM)患者常发生多种内分泌紊乱。他们也容易发生骨质疏松症和椎体骨折。BTM 患者的血浆胰岛素样生长因子 1(IGF-1)水平通常较低,其来源是多因素的。本研究旨在评估血清 IGF-1 水平与骨质疏松症和/或椎体骨折的存在之间的可能关系。
我们回顾性评估了 30 名男性 BTM 患者(平均年龄 43.3±7.9 岁)的椎体骨折发生情况,这些患者的血清 IGF-1 水平较低(中位数为 52.4ng/ml,范围为 38.5-83.4)。仅 6 名患者(20.0%)在生长激素释放激素/精氨酸刺激试验后被诊断为生长激素缺乏症(GHD),而 23 名患者(76.7%)患有骨质疏松症,12 名患者(40.0%)有已知的椎体骨折。除 1 名患者外,所有患者均至少存在一种内分泌紊乱。
与无椎体骨折的患者相比,有椎体骨折的 BTM 患者的血清 IGF-1 明显较低(U=41.0,p=0.005),而与低骨量的患者相比,血清 IGF-1 无明显差异。GHD 的诊断与较低的血清 IGF-1(p=0.001)和椎体骨折(p=0.002)显著相关,但与低骨量无关。在 ROC 分析后,我们发现非常低的 IGF-1(≤50.0ng/dl)与椎体骨折相关(敏感性 83.3%,特异性 75.0%),并且也可预测 GHD(敏感性 75.0%,特异性 100.0%)。
我们的研究表明,在男性 BTM 患者中,血清 IGF-1≤50.0ng/dl 是椎体骨折的标志物,并且可预测 GHD 的诊断。